COMMUNIQUÉS West-GlobeNewswire

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
07/10/2025
BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
TerrAscend to Host Third Quarter 2025 Earnings Conference Call
07/10/2025
TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis company, today announced that it will host a scheduled [...]
Bluejay Therapeutics Announces Data Presentations in Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at Upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025
07/10/2025
REDWOOD CITY, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver [...]
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
07/10/2025
Expanding executive leadership team to prepare for late-stage development, strategic organizational growth, and market readiness BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage [...]
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
07/10/2025
ROCKVILLE, Md. and SUZHOU, China, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company ”), a global, commercial stage, integrated [...]
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
07/10/2025
To release full third quarter 2025 financial results on November 13th; conference call to follow TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a [...]
Esaote enters the field of neurosurgery by presenting an innovative intraoperative MRI system
07/10/2025
I-Genius is the result of Esaote’s research and collaboration with neurosurgeons. The results achieved using MRI systems in brain glioma surgery were presented at EANS annual Congress held in Vienna The medical and [...]
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
07/10/2025
Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 [...]
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
07/10/2025
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less [...]
Jade Biosciences Announces $135 Million Private Placement
07/10/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
07/10/2025
Torino, Italy, October 7 – Resalis Therapeutics , a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense [...]
New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
07/10/2025
Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile Consistent efficacy demonstrated across age groups MILAN, Italy, October 07, [...]
Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents
07/10/2025
The two new patents expand protection for Salipro Biotech's proprietary technology for stabilizing and extracting challenging membrane proteins, crucial for developing therapeutics against high-value drug targets like [...]
Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer
07/10/2025
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer Oxford UK, [...]
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’ESGCT
07/10/2025
NEW YORK, 07 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
07/10/2025
Former GSK and Sanofi executive, led Cervarix ® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalist Strengthens Bioxodes leadership following encouraging Phase 2a [...]
Bioxodes nomme Philippe Monteyne, un vétéran de l’industrie pharmaceutique, au poste de président et accélère le développement en phase avancée de son candidat médicament innovant dans l’AVC
07/10/2025
Ancien dirigeant de GSK et de Sanofi, M. Monteyne a supervisé le développement de Cervarix ® et permis l’avancement de plusieurs traitements pionniers dans les maladies rares ; il apporte dix années d’expérience en [...]

Pages